Welcome to our dedicated page for TILRAY BRANDS news (Ticker: TLRY), a resource for investors and traders seeking the latest updates and insights on TILRAY BRANDS stock.
TIlray Brands, Inc. (TLRY) generates frequent news as a global lifestyle and consumer packaged goods company active across cannabis, beverage, wellness, and entertainment categories. Company updates often highlight developments in its cannabis brands, medical cannabis operations, beverage portfolio, and strategic corporate actions, giving investors and followers insight into how Tilray is executing its multi-category strategy.
News coverage commonly includes financial results and segment performance across cannabis, beverage, wellness, and distribution, as reflected in Tilray’s quarterly earnings releases. These updates may discuss trends in international medical cannabis revenue, Canadian adult-use cannabis sales, and distribution activity through Tilray Pharma. Corporate announcements, such as the implementation of a one-for-ten reverse stock split and related shareholder decisions, are also reported through press releases and SEC filings.
Tilray’s brand and product news provides detail on new launches and category expansion. Recent communications feature Dry January and holiday guides showcasing hemp-derived THC beverages, zero-proof spirits, non-alcoholic beers, and craft beers, as well as cannabis-infused beverages under brands like Mollo and XMG. Other releases focus on innovations in cannabis vapes and concentrates under brands such as Good Supply and Redecan, and curated cannabis gift guides that reflect consumer trends in Canada.
Regulatory and medical developments are another important theme. Tilray Medical has issued statements on U.S. federal cannabis rescheduling and the creation of Tilray Medical USA, outlining a framework for U.S. medical cannabis expansion based on experience in regulated international markets. For readers tracking TLRY, this news stream offers context on how the company responds to policy changes, evolves its brand portfolio, and communicates with shareholders. Bookmark this page to access an organized feed of Tilray’s earnings releases, product announcements, regulatory updates, and other material company news.
Tilray Inc. (TLRY), a leader in cannabis, will release its 2020 fiscal year and Q4 results on February 17, 2021, after market close. A conference call is scheduled for 5:00 p.m. ET, accessible via a U.S. toll-free number 877-407-0792, or internationally at 201-689-8263. The call will also be available through a live webcast on the Tilray website, which will later be archived for viewing.
Tilray Inc. (NASDAQ: TLRY) has partnered with Grow Pharma to import and distribute medical cannabis products in the UK. This agreement facilitates access for UK patients to GMP-certified medical cannabis solutions. Tilray plans to offer a range of products by March 2021, available through private practices or the NHS. According to CEO Brendan Kennedy, this partnership is a significant step in improving patient access in the UK, while Managing Director Sascha Mielcarek emphasizes the company's commitment to becoming a leading supplier as demand increases.
Tilray, a global leader in cannabis, announced its first export of GMP-certified medical cannabis from Portugal to Spain, in collaboration with Worldpharma Biotech. This shipment, approved by Spain's AEMPS, will support clinical trials for conditions such as Alzheimer's and Parkinson's. Tilray's pharmaceuticals-grade product is designed to meet stringent EU standards, enhancing patient access to reliable cannabis treatments. This milestone marks the 17th country receiving Tilray cannabis, showcasing its commitment to global medical cannabis standards.
Tilray, Inc. (NASDAQ: TLRY) has received market authorization from Infarmed in Portugal to offer its medical cannabis products, confirming compliance with strict quality and safety standards. This marks the first time a comprehensive quality dossier was required for market authorization in Europe. The approved products treat various conditions, including multiple sclerosis-related spasticity, severe seizure disorders, and chronic pain. With GMP certification, Tilray can manufacture and export medical cannabis products across the EU, catering to rising patient demand.
Tilray has been selected by the French National Agency for the Safety of Medicines and Health Products (ANSM) to supply GMP-certified medical cannabis products for experimentation in France. This initiative will last between 18 to 24 months, starting in Q1 2021, targeting patients with conditions like refractory neuropathic pain and drug-resistant epilepsy. Tilray's facility in Portugal will handle the production and export of these products. The announcement reflects Tilray's commitment to expanding operations in Europe and improving patient access to quality medical cannabis.
Tilray (Nasdaq: TLRY), a prominent player in the medical cannabis sector, has entered a co-promotion agreement with Hormosan, effective January 1, 2021. This collaboration aims to enhance marketing and sales for Tilray's full-spectrum cannabis extracts in Germany, leveraging Hormosan's expertise in pain therapy and neurology. Since launching its extracts in 2017, Tilray has expanded its offerings, which include various THC-CBD ratios, targeting chronic pain and sleep disorders. The partnership is expected to improve access for physicians and patients, ultimately benefiting patient care.
Tilray, a leader in cannabis research and distribution, has announced an agreement to exchange approximately $72.9 million in its 5.00% Convertible Senior Notes due 2023 for around 6.4 million shares of Class 2 common stock. This exchange, set to finalize by November 25, 2020, allows Tilray to reduce debt significantly and eliminate $3.6 million in annual interest costs. Post-transaction, about $277.9 million in Notes will remain outstanding. The shares from this exchange have not been registered under the Securities Act of 1933.
Tilray Inc. (Nasdaq: TLRY), a leader in cannabis cultivation and distribution, will announce its third-quarter results for the period ending September 30, 2020, on November 9, 2020, post-market close. A conference call will take place at 5:00 p.m. ET for investors, with dial-in options provided. The results will be discussed in detail during this call, and an archived webcast will be available on the company's website following the event. Tilray continues to serve thousands of patients across 15 countries globally.
Tilray's subsidiary, High Park, has launched Chowie Wowie Gummies in Canada, featuring THC Watermelon and balanced THC/CBD Pineapple Mango flavors. Each gummy contains 2.5mg of THC or a combination of THC and CBD. The affordable price is set at $6.99 per pack. These gummies are vegan, gluten-free, and made from clean ingredients, ensuring a pleasant taste without strong cannabis flavors. The product rollout commenced on September 28, 2020, across provinces including Alberta, British Columbia, and Ontario, with plans for additional flavors in the future.
Tilray (NASDAQ: TLRY) announced encouraging results from a clinical trial led by Australian researchers, demonstrating its GMP-produced cannabis product's potential to reduce chemotherapy-induced nausea and vomiting. The study, published in the Annals of Oncology, noted that 25% of patients using medicinal cannabis experienced no vomiting or nausea, compared to 14% of those on a placebo. Following this pilot phase with 81 participants, a larger trial will begin, recruiting an additional 170 participants to assess effectiveness further.
FAQ
What is the current stock price of TILRAY BRANDS (TLRY)?
What is the market cap of TILRAY BRANDS (TLRY)?
